Market Research Logo

Influenza B Infections - Pipeline Review, H2 2016

Influenza B Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Influenza B Infections - Pipeline Review, H2 2016’, provides an overview of the Influenza B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
  • The report reviews pipeline therapeutics for Influenza B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Influenza B Infections therapeutics and enlists all their major and minor projects
  • The report assesses Influenza B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Influenza B Infections
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Influenza B Infections Overview
Therapeutics Development
Pipeline Products for Influenza B Infections - Overview
Pipeline Products for Influenza B Infections - Comparative Analysis
Influenza B Infections - Therapeutics under Development by Companies
Influenza B Infections - Therapeutics under Investigation by Universities/Institutes
Influenza B Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Influenza B Infections - Products under Development by Companies
Influenza B Infections - Products under Investigation by Universities/Institutes
Influenza B Infections - Companies Involved in Therapeutics Development
AbbVie Inc.
Altravax, Inc.
Aphios Corporation
BioClonetics Immunotherapeutics, Inc.
ContraFect Corporation
Humabs BioMed SA
Johnson & Johnson
Medicago Inc.
MedImmune, LLC
Mucosis B.V.
Sanofi Pasteur SA
Vaxart, Inc.
Zydus Cadila Healthcare Limited
Influenza B Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AL-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-0205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-8033 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-8071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-9114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fluad (quadrivalent) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FluGEM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [serotypes A, B] (split virion, tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Influenza B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Influenza B Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXABYW-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influenza B Infections - Dormant Projects
Influenza B Infections - Discontinued Products
Influenza B Infections - Product Development Milestones
Featured News & Press Releases
Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial
Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Influenza B Infections, H2 2016
Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Influenza B Infections - Pipeline by AbbVie Inc., H2 2016
Influenza B Infections - Pipeline by Altravax, Inc., H2 2016
Influenza B Infections - Pipeline by Aphios Corporation, H2 2016
Influenza B Infections - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016
Influenza B Infections - Pipeline by ContraFect Corporation, H2 2016
Influenza B Infections - Pipeline by Humabs BioMed SA, H2 2016
Influenza B Infections - Pipeline by Johnson & Johnson, H2 2016
Influenza B Infections - Pipeline by Medicago Inc., H2 2016
Influenza B Infections - Pipeline by MedImmune, LLC, H2 2016
Influenza B Infections - Pipeline by Mucosis B.V., H2 2016
Influenza B Infections - Pipeline by Sanofi Pasteur SA, H2 2016
Influenza B Infections - Pipeline by Vaxart, Inc., H2 2016
Influenza B Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Influenza B Infections - Dormant Projects, H2 2016
Influenza B Infections - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Influenza B Infections, H2 2016
Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report